SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Clinical trial NCT07131319 · RECRUITING
Trial details
- NCT number
- NCT07131319
- Sponsor
- Second Affiliated Hospital of Nanchang University
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-21
- Primary completion
- 2028-10-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.